DRUG:CNSX
Bright Minds Biosciences Inc
88,40Â CA$
arrow_downward
-0,35%(-0,31) 1G
11 set, 16:00:00 GMT-4 · CAD
search
Tutti i simboli
1G
5G
1M
6M
YTD
1A
5A
MAX
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per DRUG in corso…
Apertura
91,58Â CA$
Massimo
91,58Â CA$
Minimo
88,18Â CA$
Cap. mercato
873,75Â Mln
Vol. medio
565,00
Volume
0,00
Max 52 sett.
170,00Â CA$
Min 52 sett.
64,62Â CA$
Utili per azione
-2,90Â CA$
N. di dipendenti
26
Apertura
91,58Â CA$
Massimo
91,58Â CA$
Minimo
88,18Â CA$
Cap. mercato
873,75Â Mln
Vol. medio
565,00
Volume
0,00
Max 52 sett.
170,00Â CA$
Min 52 sett.
64,62Â CA$
Utili per azione
-2,90Â CA$
N. di dipendenti
26
Profilo
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HTâ‚‚ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Informazioni su Bright Minds Biosciences Inc